Biotechnology M&A news last week featured Denmark-based Genmab’s plans to expand its portfolio with an up to $8 billion acquisition of Dutch biotech Merus along with its cancer candidate petosemtamab. On the research front, Switzerland’s MoonLake Immunotherapeutics saw its shares plunge 90% on disappointing Phase III trial results for its inflammatory disease candidate sonelokimab, and US biotech giant Amgen released new Phase III data on its cardiovascular drug Repatha. Also of note, US pharma giant Pfizer became the first drugmaker to strike a deal with government to lower medicine prices and join President Donald Trump’s Trump\Rx.gov program. 5 October 2025